SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Maurice Winn who wrote (1671)7/14/1999 9:38:00 PM
From: Bob L  Read Replies (1) of 1762
 
Maurice, I continue to follow Rituxan treatment pretty closely and have yet to see even one other mention of tuberculosis risk. Either that doctor was all wet, or is still ahead of his time. Patients do see decreased white blood counts which suggest a general risk of infection, but actual infection rates don't seem to be much of a problem.

The serious side effects you are thinking of are probably "tumor lysis syndrome" which involved severe infusion-related adverse events and a few deaths. Genentech and Idec issued a letter reminding docs to monitor the infusion more carefully. Here's your url.
fda.gov
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News